UNSPSC 51285409: Cefsumide

This classification denotes a cephalosporin antibiotic with the molecular formula C17H20N4O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3642W81J7A, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(3-((methylsulfonyl)amino)phenyl)acetyl)amino)-3-methyl-8-oxo-, (6r-(6alpha,7beta(r*)))- but more generally known as cefsumide, which bears US NIH Compound Identifier 68718.

UNSPSC 51285409 Cefsumide is a Commodity code, but the recent state and local opportunities tagged under it do not align with the code's nominal pharmaceutical scope. The opportunities instead reflect procurement of naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, direct-to-manufacturer prescription programs, and emergency medical and first aid supplies. The issuing bodies span county health departments, state pharmacy agencies, fire departments, and multistate cooperative purchasing alliances; no single repeat buyer dominates the recent activity.

The geographic spread includes Florida (Seminole County), Texas (HHS Commission), Minnesota (MMCAP cooperative), and Oregon (MMCAP participant). Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2026; the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, designated as sheltered for certified Small Local Business Enterprises with a 5% bid discount, due March 13, 2026; the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescriptions, due April 3, 2026. The code shows fragmented activity with no clear pattern of repeat procurement under the Cefsumide classification itself, suggesting either inconsistent coding practices or limited relevant market activity.